5

Goldline Pharmaceutical

544759 BSE

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%

Weaknesses

1
  • Company has high debtors of 189 days.

Growth Rate

Revenue Growth
11% lower than 3Y
Net Income Growth
42% lower than 3Y

Quarterly Results

Particulars Sep 2025Mar 2026
Sales
13.89
17.31
Expenses
11.25
13
Operating Profit
2.64
4.31
OPM %
19.01%
24.9%
Other Income
0
0
Interest
0.67
0.65
Depreciation
0.12
0.12
PBT
1.85
3.54
Tax %
26.49%
21.75%
Net Profit
1.36
2.76
EPS in Rs
1.97
4
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
19.73
23.48
28.01
31.18
Expenses
17.32
19.14
21.86
24.09
Operating Profit
2.41
4.34
6.15
7.09
OPM %
12.21%
18.48%
21.96%
22.74%
Other Income
-0.2
-0.04
-0.09
0
Interest
1.63
1.61
1.95
1.46
Depreciation
0.18
0.16
0.25
0.24
PBT
0.4
2.53
3.86
5.39
Tax %
37.5%
28.46%
26.42%
23.38%
Net Profit
0.26
1.81
2.83
4.12
EPS in Rs
1.3
7.87
4.1
5.97
Div. Payout %
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2.3
6.9
6.9
Reserves
2.08
3.76
1.55
5.54
Borrowings
12.64
12.94
12.85
10.97
Other Liabilities
2.67
3.93
4.88
5.47
Total Liabilities
19.39
22.93
26.18
28.88
Fixed Assets
2.5
2.95
2.89
2.71
CWIP
0
0.45
0
0
Investments
0.07
0.03
0.03
0.03
Other Assets
16.82
19.5
23.26
26.14
Total Assets
19.39
22.93
26.18
28.88
Figures in ₹ Crores

Cash Flow

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2.39
2.92
3.18
2.81
Investing
-1.04
-1.11
0.16
-0.06
Financing
-1.44
-1.08
-2.89
-3.4
Net Cash Flow
-0.09
0.74
0.45
-0.65
Free Cash Flow
1.38
1.81
3.35
2.75
CFO/OP
101
72
66
53
Figures in ₹ Crores

Ratios

Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
160
150
139
189
Inventory Days
336
450
229
202
Days Payable
54.47
98.62
69.62
60.29
Cash Conversion Cycle
441
501
299
331
Working Capital Days
144
133
134
156
ROCE %
—
23.4%
29.28%
30.64%

Shareholding Pattern

FIIs5.16%Promot.57.29%DIIs7.81%Public29.74%As ofMay 2026
A trend needs at least two reported periods.

Documents

Frequently Asked Questions about Goldline Pharmaceutical

What does Goldline Pharmaceutical Ltd do?
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]
Where is Goldline Pharmaceutical Ltd (544759) listed?
Goldline Pharmaceutical Ltd trades under code 544759 on the BSE.
Which sector does Goldline Pharmaceutical Ltd belong to?
Goldline Pharmaceutical Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.

Company Information

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]

Website goldlinepharma.in
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544759.md for Goldline Pharmaceutical Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List